Arovella Therapeutics Ltd has released a press release.
ArTiMist Regulatory Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Appendix 4C Amended
- SUDA Signs Agreement With Mitsubishi Tanabe
- ZLD to Invest in Development of Oral Spray Formulations
- SUDA Enters Agreement To Develop Cannabinoid Spray
- SUDA Receives R&D Tax Incentive Refund
Later from Arovella Therapeutics
- Product Development Market Update
- Rights Issue To Raise Up To $3.44 Million
- Prospectus For Renounceable Pro Rata Offer
- SUDA SIgns Binding Term Sheet With Cann Pharmaceutical
- Rights Issue Closes Significantly Oversubscribed
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics